3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Unknown
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gastrointestinal
2
Thoracic
1
Sarcoma
1
Other solid neoplasm
1
NET
1
Head & Neck
1
Genitourinary
1
Endocrine
1
Breast
1
Conditions
Thyroid Neoplasms
2
Stomach Neoplasms
2
Squamous Cell Carcinoma of Head and Neck
2
Glioblastoma
2
Esophageal Squamous Cell Carcinoma
2
Carcinoma, Transitional Cell
2
Carcinoma, Renal Cell
2
Carcinoma, Non-Small-Cell Lung
2
Astrocytoma
2
Uterine Cervical Neoplasms
1
Turcot syndrome
1
Triple Negative Breast Neoplasms
1
Tertiary Lymphoid Structures
1
Small Cell Lung Carcinoma
1
Sarcoma
1
Neoplasm Metastasis
1
Mesothelioma, Malignant
1
Melanoma
1
Gastro-enteropancreatic neuroendocrine tumor
1
Esophageal Neoplasms
1
Colorectal Neoplasms
1
Central Nervous System Neoplasms
1
Carcinoma, Squamous Cell
1
Carcinoma, Merkel Cell
1
Carcinoma, Hepatocellular
1
Brain Neoplasms
1
Biliary Tract Neoplasms
1
Interventions
pembrolizumab
5
Nivolumab
2
trifluridine tipiracil drug combination
1
tremelimumab
1
trametinib
1
regorafenib
1
niraparib
1
larotrectinib
1
futibatinib
1
durvalumab
1
dostarlimab
1
dabrafenib
1
cemiplimab
1
TAS-116
1
Ramucirumab
1
Itraconazole
1
Gemcitabine
1
Fluorouracil
1
Docetaxel
1
Clinical Trials, Phase II as Topic
1
Cisplatin
1
Carboplatin
1
Bevacizumab
1
Antibodies
1
4-(2-fluoro-4-((((2-phenylacetyl)amino)thioxomethyl)amino)phenoxy)-7-methoxy-N-methyl-6-quinolinecarboxamide
1
130-nm albumin-bound paclitaxel
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Biliary Tract Neoplasms
×
regorafenib
×
Head & Neck
×
Clear all
NCT03475953
2023-03-03
REGOMUNE
Institut Bergonié
Phase 1/2
Unknown
747 enrolled